Skip to main content

Q/C Technologies, Inc.

QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001321834

No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Q/C Technologies, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of QCLS: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders4851+3
Shares4.34M4.26M−84.9K (−2.0%)
Value$6.51M$2.52M−$3.99M (−61.3%)

New holders (12)

Institutions that held Q/C Technologies, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to QCLS in Q3 2023
InstitutionSharesValue% of portfolio
Atlas Brown,Inc.43,500$25.8K0.01%
XTX Topco Ltd39,544$23.4K0.00%
Wealth Enhancement Advisory Services, LLC18,690$11.1K0.00%
LVZ Advisors, Inc.16,343$9.68K0.00%
HighTower Advisors, LLC12,664$9.00K0.00%
Cary Street Partner Investment Advisory LLC14,471$8.57K0.00%
UBS Group AG6,258$3.71K0.00%
Newbridge Financial Services Group, Inc.500$2960.00%
Qube Research & Technologies Ltd66$390.00%
JPMorgan Chase & Co42$250.00%
Focused Wealth Management, Inc11$60.00%
Cornerstone Planning Group LLC1$10.00%

Sold out (9)

Institutions that held Q/C Technologies, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.